(Adds details on Eylea, Dupixent sales, background)
Aug 6 (Reuters) - Regeneron Pharmaceuticals Inc beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by demand for its blockbuster eye treatment Eylea and eczema drug Dupixent.
Sales of Eylea, which treats diseases of the eye including age-related macular degeneration, jumped 17% in the United States in the latest quarter even as it faces competition from Roche Holding AG and Novartis AG's Lucentis.
Eylea's sales of $1.16 billion also topped expectations of about $1.10 billion, according to consensus estimates compiled by brokerage Credit Suisse.
The drug, which accounts for more than half of total revenue, is expected to lose its patents in the next five years
To reduce its reliance on Eylea, Regeneron is focusing on Dupixent and has massed up approvals for three major diseases including asthma and nasal polyps since the drug was approved in 2017.
Dupixent's quarterly sales jumped nearly three-fold to $557.3 million.
Total revenue rose 20.3% to $1.93 billion in the second quarter ended June 30, beating the average analyst estimate of $1.80 billion, according to IBES data from Refinitiv.
Excluding one-time items, the company earned $6.02 per share, above the average analyst estimate of $5.41.
(Reporting by Manas Mishra and Shivani Singh; Editing by Maju Samuel and Sriraj Kalluvila)